Key Highlights
- Nura Bio closes $140M Series A financing to support clinical development.
- Shilpa Sambashivan, Ph.D., appointed as CEO following Phase 1 success of NB-4746.
- NB-4746 is a brain-penetrant SARM1 inhibitor with potential neuroprotective benefits.
- Phase 1 trial results show NB-4746 was well-tolerated and achieved target plasma exposure.
Source: Business Wire
Notable Quotes
- “Under Shilpa’s leadership, Nura Bio has successfully transitioned to a clinical-stage organization, making remarkable progress in identifying ways to translate complex biology into potential therapies.” — Tim Kutzkey, Ph.D., Managing Partner at The Column Group
- “I look forward to leading the company through this next phase as we prepare to test the SARM1 hypothesis in a patient population in 2025.” — Shilpa Sambashivan, Ph.D., CEO at Nura Bio
SoHC's Take
The successful closing of over $140M in Series A financing for Nura Bio underscores the increasing investor confidence in the company’s neuroprotective research and therapeutic pipeline. With NB-4746 progressing successfully through Phase 1 trials, Nura Bio is well-positioned to address significant unmet needs in the treatment of neurological diseases. Shilpa Sambashivan’s appointment as CEO is a strategic move, leveraging her deep scientific expertise and leadership to guide the company toward achieving its ambitious clinical milestones in the coming years.
Heading
Key Highlights Shore Capital Partners launches Agentis Longevity to lead the longevity healthcare sector. Jimmy St Louis named CEO, bringing expertise from Regenerative Medicine ...
Key Highlights Nymbl Systems announces strategic partnership with Frontier Growth to accelerate growth and innovation. Frontier Growth brings 25+ years of growth equity expertise to ...
Key Highlights Launch of fingertip blood collection technology using BD’s MiniDraw™ and Babson’s BetterWay for U.S. health systems. Revolutionizes access with fewer ...
Key Highlights Anatomy Financial raises $19M in Series A funding, led by Canapi Ventures. Neil Underwood (Canapi) and Nicole Quinn ...
Key Highlights Wendy Barnes to assume role as GoodRx CEO on January 1, 2025. Brings 30+ years of leadership in pharmacy and healthcare benefit industries. Former CEO of RxBenefits and President of Express ...
Key Highlights Mike Butler, former Providence president, joins Linus Health's board of directors. Butler brings decades of healthcare leadership and ...
